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ABSTRUCT 
Radiation-induced organizing pneumonia (OP) reportedly occurs in ~2% of patients 
who receive whole-breast radiotherapy (WBRT). Though there are several reported risk 
factors, they remain unclear and controversial. We analyzed the incidence of and risk 
factors for OP after WBRT at our institution. We analyzed 665 breast cancer patients (with 
WBRT of 679 breasts) who underwent WBRT from October 2007 to September 2012 at 
our institution and were followed up for more than 1 year after completion of WBRT. 
Factors included in the analysis were age, the side affected, central lung distance (CLD), 
radiation dose, concurrent endocrine therapy, and chemotherapy. 
The median age was 56 years (range, 23-89 years). The sides affected were left, right 
and bilateral in 342, 309 and 14 patients, respectively. The median CLD was 1.1 cm 
(range, 0-3.0 cm). Concurrent endocrine therapy was performed in 236 patients, and 
chemotherapy was given in 215 patients; of these, 4 received concurrent chemotherapy. 
OP developed in nine patients (1.4%). The median time taken to develop OP after the 
completion of WBRT was 4 months (range, 2-12 months). All nine patients were treated 
with steroids, and symptoms promptly improved, except in two patients who relapsed. 
Statistical analysis revealed that only CLD (≥1.5 cm) was significantly associated with 
the development of OP (P = 0.004). 
In conclusion, the incidence of OP after WBRT was 1.4%, and CLD was a significant 
risk factor. In these patients, OP was controlled with steroid administration. 
 
ABBREVIATIONS 
OP : Radiation-induced organizing pneumonia 
WBRT : whole-breast radiotherapy 
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CLD : central lung distance 
fr. : fraction 
V20 : lung volume irradiated at 20Gy 
FEC : 5-fluorouracil+epirubicin+cyclophosphamide 
TC : docetaxel+cyclophosphamide 
CMF : cyclophosphamide+methotrexate+5-fluorouracil 
EC : epirubicin+cyclophosphamide 
5-FU : 5-fluorouracil 
AI : aromatase inhibitor 
TAM : tamoxifen 
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INTRODUCTION 
Historically, until the 1980s, based on the Halsted theory which stated that the prognosis 
of breast cancer patients was dependent on the maximal excision of the breast and 
lymphatic pathways, the main surgical approach had been the extensive excision of the 
breast including whole breast and lymphatic pathway and large pectoralis muscle and 
pectoralis muscle [1]. Radiation therapy of this age had been the irradiation of the chest 
wall, axillary, supraclavicular, parasternal lymph region using a Co60 source, and the side 
effects such as dermatitis and OP were strong.  
Around 1990s, based on the Fisher theory that breast cancer is a systemic disease at the 
time of diagnosis and, therefore, the difference in surgical therapy does not affect 
prognosis, reduction surgery such as pectoral muscle preserving or breast conserving 
surgery has become the mainstream surgery is well accepted that the local therapy can 
lead to the eradication of the disease [2]. The Early Breast Cancer’ Collaborate Group 
reported that the local control and the overall survival at 15 years were significantly 
improved by the addition of WBRT after breast-conserving surgery [3]. In Japan, the 
combination of breast conserving surgery and WBRT is the current standard treatment 
and performed in more than 80% of early breast cancer cases [4]. 
WBRT has been performed as standard therapy for early-stage breast cancer after breast-
conserving surgery. Recently, endocrine therapy and chemotherapy have been commonly 
used with WBRT, concurrently or sequentially. Although the most frequent adverse effect 
of WBRT is acute dermatitis, OP is a well-known adverse effect that is rare but significant. 
Radiation-induced OP is reported to occur in ~1-3% of breast cancer patients who receive 
postoperative WBRT [5-13]. 
By definition [14], OP occurs within 12 months after WBRT. Onset of OP is usually 
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reported to be within 6 months [15]. Risk factors reported in previous studies include 
none [6,7], age [8,9], large irradiated lung volume [10], concurrent endocrine therapy [8], 
and smoking [9]. However, the significance of these risk factors remains unclear and 
controversial because of the rarity of OP.  
In this report, we studied a total of 665 breast cancer patients (with WBRT of 679 
breasts) who underwent WBRT during a period of 5 years at our institution to analyze the 
incidence of OP and risk factors for OP after WBRT. 
 
MATERIALS AND METHODS/PROCEDURES 
 Ethics statement 
This retrospective study was approved by the institutional review board of Fukushima 
Medical University Hospital, Fukushima City, Japan (IRB approval number 1606). 
Anonymity of the patients was preserved. 
 
Patient characteristics 
Between October 2007 and September 2012, 686 newly diagnosed breast cancer 
patients received WBRT at Fukushima Medical University Hospital after breast-
conserving surgery as an initial treatment. Overall, 665 patients (97%) (with WBRT of 
679 breasts) were followed up for more than 12 months. Those lost to follow-up within 
12 months were excluded from this analysis. The sides affected were left, right and 
bilateral in 342, 309 and 14 patients, respectively. Table 1 shows the patient characteristics 
of this study. The median age of the 665 patients was 56 years (range, 23-89 years) and 
the median follow up period was 643days (range, 370-2230 days). 
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Treatments 
 Radiotherapy 
All patients were treated with WBRT after breast-conserving surgery at our institution 
or our neighboring hospital. WBRT was primarily performed with 6-MV X-rays using 
two tangential photon beams or four beams with the field-in-field technique to a total dose 
of 50 Gy/25 fractions/5 weeks. Nine patients with lobular carcinoma were treated with 
54 Gy/27 fractions. Breasts with a positive surgical margin were irradiated with an 
additional 10 Gy/5 fractions using an optimal electron beam. WBRT for both sides was 
concurrently performed in 14 patients with bilateral cancer. 
 
Endocrine therapy and chemotherapy 
The details of the endocrine therapy and chemotherapy are shown in Table 1. In this 
study, administration of chemotherapy within the 3 weeks before and/or after WBRT was 
classified as ‘concurrent use of chemotherapy’. Endocrine therapy was administered to 
507 patients (74.7%), and 241 patients received concurrent endocrine therapy. 
Chemotherapy was administered to 219 patients (32.3%), of whom 212 received 
chemotherapy before WBRT and only 4 received concurrent chemotherapy. In 2 of those 
4 cases, the chemotherapy was administered a short time before WBRT or with a limited 
overlap time because of the patients’ difficulties in travelling to our hospital. In the other 
2 cases, chemotherapy was only limited to an oral agent in relatively high-risk patients 
who refused standard therapy. The Japanese guideline has not recommended concurrent 
administration of chemotherapy and WBRT since 2011, but these 4 patients were all 
treated before 2011. 
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Diagnosis of OP 
In general, all patients were followed up and checked for OP at 1, 3, 9, 15 and 21 months 
after completion of WBRT. At 3 months after WBRT, OP was checked with chest X-ray 
and/or chest CT. Diagnosis of OP was performed on the basis of the clinical diagnostic 
criteria proposed by Crestani et al. [5]: (i) radiation therapy to the breast within 12 months, 
(ii) general and/or respiratory symptoms lasting for at least 2 weeks, (iii) lung infiltrates 
outside the radiation port, and (iv) no specific cause. 
 
 Evaluation of identifying risk factor 
Factors included in the analysis were age <50 or ≥50 years, the side affected (right or 
left, lateral or bilateral), central lung distance (CLD; <1.5 or ≥1.5 cm), radiation dose (50 
Gy or 50 Gy+boost), concurrent endocrine therapy (with or without), and chemotherapy 
(with or without). CLD was measured as the farthest distance between the posterior 
border of the irradiation field and the chest wall on approved linacgraphy. 
 
Statistical analysis 
Statistical analyses were performed using the chi-square test with SPSS 21 (SPSS, 
Chicago, IL). Differences were considered significant when P values were less than 0.05. 
The cumulative occurrence rate of OP was calculated using the Kaplan-Meier method 
with SPSS 21. 
 
RESULTS 
Figure 1 shows the cumulative OP occurrence rate. OP developed in 9 (1.4%) of 679 
irradiated breasts (665 patients). Six of the nine patients (67%) developed OP in the first 
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6 months. 
Table 1 shows the study patients’ clinical characteristics. The median CLD was 1.1 cm 
(range, 0-3.0 cm). Among 665 patients, 236 were treated with concurrent endocrine 
therapy. Chemotherapy was given to 215 patients; of these, 4 had concurrent 
chemotherapy. 
Table 2 shows the results of univariate analysis of possible risk factors. Statistical 
analysis revealed that CLD was significantly associated with the development of OP (P 
= 0.004), whereas other factors were not. 
Table 3 shows the details of the nine patients who developed OP. The median time for 
developing OP after the completion of WBRT was 4 months (range, 2-12 months). All 
nine patients presented with mild fever and/or cough and were treated with steroids. Two 
OP patients relapsed and were treated with repeat steroid administration, and a patient 
who relapsed three times remained on low-dose steroid therapy 6 years after the initial 
onset of OP. 
 
DISCUSSION 
As previously reported, OP occurs in ~1-2% of breast cancer patients who receive 
WBRT. The risk factors for OP remain unclear and controversial, although several factors, 
such as age, endocrine therapy, and large irradiated lung volume, have been reported as 
risk factors in previous studies [6-9,11]. 
Katayama et al. reported that age (≥50 years) was a risk factor for OP in breast cancer 
patients treated with WBRT [8]. In addition, Murofushi et al. claimed that age was 
associated with OP in breast cancer patients treated with radiotherapy but not in patients 
treated with breast-conserving treatment [9]. Many reports [6,7,10,11], including this 
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study, did not show age to be a risk factor. However, caution should be given when 
treating elderly patients because older age is reportedly an important risk factor for OP in 
patients treated for other diseases, such as lung cancer, using modern radiotherapy 
techniques [16].  
Murofushi et al. also reported that smoking was a risk factor for the development of OP 
[9]. However, in this study, none of the nine patients who developed OP had a history of 
smoking, and significance of smoking in the development of OP was not shown. 
Concurrent use of endocrine therapy has been reported as a risk factor for OP [8], 
whereas other reports show no correlation [9,12]. In our current practice, we allow the 
concurrent use of endocrine therapy when needed because no significant correlation with 
the development of OP was shown in this study. Most reports have shown that 
chemotherapy has no significant correlation with the development of OP, and this study 
also found no correlation. 
 However, Caudia et al. reported that symptomatic OP patients had a bronchoalveolar 
lavage (BAL) with significantly increase in total cells compared to BAL in asymptomatic 
patients with predominance of T lymphocytes [17]. Naozumi at al. reported that estrogen 
deficiency may play a role on acceleration of organ-specific autoimmune in murine 
Sjögren’s Syndrome [18]. Wirsdorfer et al. reviewed the role of lymphocytes in 
radiotherapy-induced adverse late effects in the lung in detail [19]. 
Therefore, the use of drugs affecting host-immune status or immune cell activity may 
be related to the development or prevention of OP, and attention may be required 
regarding which type of chemotherapeutic agents are to be used when concurrent 
chemotherapy is considered. 
In lung cancer patients treated with radiotherapy, the lung volume irradiated at 20 Gy 
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(V20) has been considered as a risk factor for radiation-induced pneumonia [20]. In breast 
cancer patients treated with WBRT, Kubo et al. reported that >1.8 cm of CLD was 
significantly correlated with the incidence of OP, but lung V20 was not [10]. In addition, 
we found that ≥1.5 cm of CLD was significantly correlated with OP in this study, although 
data for V20 were not available. Murofushi et al. analyzed more than 1000 breast cancer 
patients and reported that V20 was not a significant factor in predicting the development 
of OP in breast cancer patients treated with radiotherapy, including post-mastectomy 
radiotherapy [9]. Paradoxically, Katayama et al. reported that ≥3 cm of CLD was not a 
risk factor for OP after WBRT [8]. Although it remains unclear whether irradiated lung 
volume affects the development of OP in breast cancer patients treated with WBRT, larger 
irradiated lung volume is considered a strong risk factor for OP according to reports in 
lung and esophageal cancer patients treated with radiotherapy. Therefore, irradiated lung 
volume should be carefully evaluated when making a treatment plan, and patients with a 
large irradiated lung volume and/or CLD should be followed up carefully for possible 
incidence of OP. Furthermore, for patients who may have a large CLD and irradiated lung 
volume, such as those with funnel chest, treatment with Intensity Modurated 
Radiotherapy(IMRT) or special irradiation technique may be an option for avoiding the 
risk of OP.  
As for the treatment for OP, we administered steroids in all nine OP patients, and they 
have taken various clinical courses. At follow up, the condition of two patients improved 
quickly after a short period (<2 months) of small-dose steroid administration. Conversely, 
six patients needed steroids for more than 6 months; of these, two patients had a relapse 
of OP, and one of them remained on small-dose steroid therapy 6 years after the initial 
onset of OP because of multiple relapses.  
11 
 
Ogo et al. reported that all 10 patients in their study improved without steroid 
administration within 3 months [7], and Murofushi et al. reported that only 2 of 16 OP 
patients required steroid treatment [9]. According to these previous reports, steroid 
therapy may not be for all patients. Otani et al. reported that steroid treatment increased 
the recurrence of radiation-induced OP after WBRT [13]. Furthermore, Oie et al. reported 
that four of five OP patients relapsed and that the durations of steroid administration were 
more than 6 months [11].  
Unfortunately, these reports were not randomized studies because of the rarity of OP, 
and the mechanism for steroid therapy for radiation-induced OP has not been elucidated. 
Although steroid administration is still the mainstay of treatment [21], symptom-oriented 
management as proposed by Otani et al. [14] may be a noteworthy consideration in the 
treatment of radiation-induced OP. 
In conclusion, the incidence of OP after WBRT was 1.4%, which is similar to the 
findings of previous reports. OP developed within 2-12 months after WBRT, and most 
patients improved with steroid administration. The only risk factor for OP was CLD ≥ 1.5 
cm. Our study suggests that patients treated with long CLD should be carefully observed 
after WBRT. 
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FIGURES 
Fig. 1 : Cumulative organizing pneumonia occurrence rate 
 The vertical axis shows the cumulative occurrence rate, the horizontal axis shows 
months after WBRT. 
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Table 1 : Patient characteristics 
Age   
     Male 0  
     Female 665  
Side   
     Left 342  
     Right 309  
     Bilateral 14  
Age Median 56y 
 (range 23-89) 
     ＜50 
213  
     ≧50 466  
Dose   
     50Gy/25fr. 491  
     54Gy/27fr. 9  
     50Gy/25fr.+Boost 10Gy/5fr. 179  
Central lung distance Median 1.1cm 
 (range 0-3.0) 
     ＜1.5cm 474 
 
     ≧1.5cm 205  
Endocrine Therapy   
  Yes(concurrent) 241  
      Anti-estrogen 36  
      Aromatase inhibitor 165  
      LH-RH analog+Anti-estrogen 40  
  Yes(after WBRT) 257  
      Antiestrogen 90  
      Aromatase inhibitor 133  
      LH-RH analog+Anti-estrogen 30  
      Unknown 4  
  Yes(period unknown) 9  
      Aromatase inhibitor 7  
18 
 
      Unknown 2  
  No 168  
  Unknown 4  
Chemotherapy   
  Yes 291  
      before WBRT 208  
      Bwfore+concurrent 4  
      After WBRT       7  
        FEC+Taxiane 146  
     FEC 23  
        TC 28  
        CMF 10  
        Taxane 3  
        EC 1  
        EC+Taxane 2  
        5-Fu 6  
  No 460  
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Table 2 : Univariate analysis of variables 
 Valuables n OP % P value 
Age 
＜50 
213 2 0.9 0.552 
 ≧50 466 7 1.5  
Side Left 342 5 1.5 0.855* 
 Right     309 4 1.3      
 Bilateral 14 0 0 0.658** 
Dose 50Gy+boost 179 2 1.1 0.912 
    50Gy 491 6 1.2  
CLD 
＜1.5cm 
474 2 0.4 0.004 
 ≧1.5cm 205 7 3.4    
Endocrine therapy        
 With 507 6 1.2 0.555 
 Without 168 3 1.8  
 Concurrent 241 5 2.1 0.218 
 Other 429 4 0.8  
Chemotherapy      
 With 219 4 1.8 0.425 
 Without 460 5 1.1  
＊The comparisons is ‘left’ vs ‘right’. 
＊＊The comparisons is ‘unilateral’ vs ‘bilateral’. 
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Table 3 : Clinical characteristics of nine patients 
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